Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals

Infection Control and Hospital Epidemiology

Volumn 31, Issue 5, 2010, Pages 485-490

  Eagye, Kathryn J ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERTAPENEM; IMIPENEM; MEROPENEM;

ANTIBIOTIC SENSITIVITY; ARTICLE; HUMAN; PSEUDOMONAS INFECTION;

ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; HOSPITALS; HOSPITALS, TEACHING; HUMANS; MICROBIAL SENSITIVITY TESTS; PHYSICIAN'S PRACTICE PATTERNS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; UNITED STATES;

EID: 77951041524     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/652154     Document Type: Article

References (20)

1. Livermore DM, CarterMW, Bagel S, et al. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother 2001;45(6):1860-1867.
2. Fuchs PC, Barry AL, Brown SD. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001;45(6):1915-1918. (Pubitemid 32466375)
3. Livermore DM, Mushtaq S, Warner M. Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems. J Antimicrob Chemother 2005;55(3):306-311. (Pubitemid 40425453)
4. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob Agents Chemother 2004;48(8):3086-3092. (Pubitemid 38989178)
5. Goff DA, Mangino JE. Ertapenem: no effect on aerobic gram-negative susceptibilities to imipenem. J Infect 2008;57(2):123-127.
6. Lima AL, Oliveira PR, Paula AP, Zumiotti AV. Influence of ertapenem administration on the incidence of carbapenem-resistant Pseudomonas aeruginosa. Braz J Infect Dis 2008;12(2):105-106.
7. Vali L, Hamouda A, Schnieders T, Amyes SGB. The potential for the emergence of carbapenem resistance when weaker carbapenems are prescribed. In: Program and abstracts of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America 46th Annual Meeting. 2008. Washington, DC. Abstract C1-107.
8. Beovic B, Kreft S, Seme K, Cizman M. Does use of ertapenem influence carbapenem resistance in Pseudomonas aeruginosa? In: Program and abstracts of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America 46th Annual Meeting. 2008. Washington, DC. Abstract C2-210.
9. Crank CW, Segreti J, Hota B. Effect of ertapenem use on Pseudomonas aeruginosa susceptibility to carbapenems. In: Program and abstracts of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy/ Infectious Diseases Society of America 46th Annual Meeting. 2008. Washington, DC. Abstract K-3502.
10. Peterson LR. Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance. Clin Microbiol Infect 2005;11(suppl 5):4-16.
11. Falagas ME, Kopterides P. Risk factors for the isolation of multidrugresistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 2006;64(1):7-15. (Pubitemid 44161380)
12. Paramythiotou E, Lucet JC, Timsit JF, et al. Acquisition of multidrugresistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis 2004;38(5): 670-677. (Pubitemid 38333863)
13. WHOCC ATC/DDD Index. http://www.whocc.no/atcddd/. Accessed June 1, 2009.
14. Schwaber MJ, De-Medina T, Carmeli Y. Epidemiological interpretation of antibiotic resistance studies-what are we missing? Nat Rev Microbiol 2004;2(12):979-983. (Pubitemid 39562536)
15. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32(8):470-485.
16. Jones RN. Global epidemiology of antimicrobial resistance among community- acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Semin Respir Crit Care Med 2003;24(1):121-134.
17. Rosenthal VD, Maki DG, Mehta A, et al. International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008. Am J Infect Control 2008;36(9):627-637.
18. Pakyz AL, Oinonen M, Polk RE. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenemresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009;53(5): 1983-1986.
19. Pakyz A, Powell JP, Harpe SE, Johnson C, Edmond M, Polk RE. Diversity of antimicrobial use and resistance in 42 hospitals in the United States. Pharmacotherapy 2008;28(7):906-912. (Pubitemid 351875169)
20. Eagye KJ, Kuti JL, Nicolau DP. Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol 2009;30(8):746-752.